Early Research Suggests that Understanding the Fundamental Mechanism of Angiogenesis is More Complicated Than Understanding the Function of VEGF - A
Amgen Launches Angiogenesis Website
THOUSAND OAKS, Calif.,
Data will be presented on investigational compounds AMG 386, a peptibody that binds to and inhibits angiopoietins 1 and 2; AMG 479, a fully human monoclonal antibody antagonist of the type 1 insulin-like growth factor receptor (IGF-1R) and AMG 102, a fully human monoclonal antibody antagonist of HGF, the ligand for the c-Met receptor.
"The data being presented at this meeting further our biologic
understanding of these novel compounds and pathways, and inform our thinking
regarding opportunities to develop predictive or prognostic biomarkers," said
Selected Abstracts of Interest
-- Assessment of angiogenesis inhibitors in the retinopathy of
prematurity model in mice
Overview: Examined the inhibition of the VEGF/VEGFR pathway with AMG
273 and the inhibition of the angiopoietin/Tie2 pathway with AMG 386
Lead author: Estrada J.
Abstract No. 140 (
-- Involvement of the CSF-1/CSF-1R interaction in the control of
angiogenesis
Overview: Two different neutralizing rat anti murine CSF-1R monoclonal
antibodies (mAb), M279 and AFS98 were evaluated for their effect on
mouse corneal angiogenesis and corneal macrophage recruitment in vivo
Lead author: Liu H.
Abstract No. 1106 (
-- Complementary and opposing effects of angiopoietin-1 and
angiopoietin-2 inhibitors on tumor blood vessels and normalization
Overview: Aimed to elucidate the effects of Angiopoietin (Ang) 1 and
Ang2 on the tumor vasculature of a human colon carcinoma model
(Colo205) using peptide-Fc fusion proteins (peptibodies) specifically
targeting Ang1 (mL4-3) or Ang2 (L1-7(N)) alone or in combination
Lead author: Falcon B.
Abstract No. 1996 (
-- AMG 479, a novel IGF-1R antibody, inhibits endometrial cancer cell
proliferation through disruption of the P13K/Akt and MAPK pathways
Overview: Evaluated the effect of a novel antibody to the IGF-1R (AMG
479) on cell proliferation and expression of key targets involved in
IGF-1R signaling in endometrial cancer cells
Lead author: Mendivil A.
Abstract No. 2804 (
-- AMG 479, a fully human anti-IGF-1R monoclonal antibody, inhibits
rapamycin-induced Akt activation in sarcoma cell lines
Overview: Evaluated whether AMG 479 could inhibit this feedback-loop
mechanism and thus increase the efficacy of rapamycin and its analogs
(mTOR inhibitors).
Lead author: Beltran P.
Abstract No. 2805 (
-- Dual targeting of the receptor tyrosine kinase EGFRvIII and HGF:c-Met
signaling in models of glioblastoma multiforme (GBM)
Overview: Examined the effect of combining a fully human neutralizing
antibody targeting the HGF:c-Met axis (AMG 102), with a fully human
antibody binding to the EGFR and EGFRvIII (panitumumab) to overcome
resistance to HGF:c-Met based therapeutic strategies in GBM
Lead author: Johns T.
Abstract No. 2044 (
-- Antagonistic antibodies to c-fms block c-fms-mediated activities,
reduce tumor-associated macrophages and decrease tumor growth in
preclinical models
Overview: Antagonistic antibodies to c-fms were evaluated for their
effects on monocytic cell function in vitro and tumor-associated
macrophages (TAMs) and tumor growth in vivo
Lead author: Bonham L.
Abstract No. 2077 (
-- Erythropoietin Receptor (EpoR) Was Expressed at Low to Undetectable
Levels in Tumor Cell Lines: Expression Was Not Regulated by Hypoxia
and No Epo-Induced Downstream Signaling Was Detectable
Overview: EpoR, mRNA and protein expression were surveyed in 67
tumor-derived cell lines from ovary, breast, head and neck, lung,
brain, prostate, cervix, liver, colon and blood
Lead author: Swift S.
Abstract No. 4283 (
Amgen Launches Educational Interactive Angiogenesis Website
About
Forward-Looking Statements
This news release contains forward-looking statements that are based on
management's current expectations and beliefs and are subject to a number of
risks, uncertainties and assumptions that could cause actual results to differ
materially from those described. All statements, other than statements of
historical fact, are statements that could be deemed forward-looking
statements, including estimates of revenues, operating margins, capital
expenditures, cash, other financial metrics, expected legal, arbitration,
political, regulatory or clinical results or practices, customer and
prescriber patterns or practices, reimbursement activities and outcomes and
other such estimates and results. Forward-looking statements involve
significant risks and uncertainties, including those discussed below and more
fully described in the
No forward-looking statement can be guaranteed and actual results may differ materially from those we project. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, preclinical results do not guarantee safe and effective performance of product candidates in humans. The complexity of the human body cannot be perfectly, or sometimes, even adequately modeled by computer or cell culture systems or animal models. The length of time that it takes for us to complete clinical trials and obtain regulatory approval for product marketing has in the past varied and we expect similar variability in the future. We develop product candidates internally and through licensing collaborations, partnerships and joint ventures. Product candidates that are derived from relationships may be subject to disputes between the parties or may prove to be not as effective or as safe as we may have believed at the time of entering into such relationship. Also, we or others could identify safety, side effects or manufacturing problems with our products after they are on the market. Our business may be impacted by government investigations, litigation and products liability claims. We depend on third parties for a significant portion of our manufacturing capacity for the supply of certain of our current and future products and limits on supply may constrain sales of certain of our current products and product candidate development.
In addition, sales of our products are affected by the reimbursement policies imposed by third-party payors, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment as well as U.S. legislation affecting pharmaceutical pricing and reimbursement. Government and others' regulations and reimbursement policies may affect the development, usage and pricing of our products. In addition, we compete with other companies with respect to some of our marketed products as well as for the discovery and development of new products. We believe that some of our newer products, product candidates or new indications for existing products, may face competition when and as they are approved and marketed. Our products may compete against products that have lower prices, established reimbursement, superior performance, are easier to administer, or that are otherwise competitive with our products. In addition, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors and there can be no guarantee of our ability to obtain or maintain patent protection for our products or product candidates. We cannot guarantee that we will be able to produce commercially successful products or maintain the commercial success of our existing products. Our stock price may be affected by actual or perceived market opportunity, competitive position, and success or failure of our products or product candidates. Further, the discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations.
The scientific information discussed in this news release related to our
product candidates is preliminary and investigative. Such product candidates
are not approved by the
Contacts:
Arvind Sood, 805-447-1060 (investors)
(Logo: http://www.newscom.com/cgi-bin/prnh/20081015/AMGENLOGO)
SOURCE